It’s the season for respiratory illnesses, especially the flu, COVID and RSV. If you contract one of these sicknesses in ...

CAPR’s lead product candidate and only clinical ... weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years.

CAPr mtDNA was detectable in many tissues at ... mutants that carry drug resistance and are known to be detrimental to respiratory chain function would have to be used. Successful breeding of ...

Cell therapy developer Capricor Therapeutics (NASDAQ:CAPR) announced Thursday the completion of the U.S. marketing application for its lead candidate, deramiocel, for patients with Duchenne ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...